Aurobindo Through the Years
Creation of a Leading Vertically Integrated Platform
Auro Packaging – Packaging Division.
Acrotech Biopharma – Brand Division. Acquired seven marketed oncology products from Spectrum Pharmaceuticals.
Opened 567,000 sq. ft. fully automated state-of-art distribution center in East Windsor, NJ
Opened a new, 40,000 sq. ft. specialty pharma R&D facility in Durham, NC
APL acquired 4 cell culture-derived biosimilar products from Swiss TL Biopharmaceutical. Three out of the four biosimilars are monoclonal antibodies in oncology.
APL acquires Portugal’s Generis Farmaceutica SA
Aurobindo Pharma USA, Inc. moves Corporate Headquarters to East Windsor, NJ, USA
Investment into Tergene to fund the development of a pneumonia vaccine
Aurobindo Pharma USA, Inc. acquires Natrol Inc. in California, USA
Aurohealth LLC begins doing business in Lawrenceville, NJ, USA
Focus on differentiated technology platforms eg. depot injections
APL acquires commercial operations in Western Europe from Actavis making it one of the leading Indian pharmaceutical companies in Europe.
Commenced marketing specialty injectables to fund the development in USA through AuroMedics
Building capabilities in Penem, Oncology & Biocatalysis
First approval of Controlled Substance formulations in USA
Set up AuroPeptide to foray into peptide business
Aurohealth LLC, our OTC division becomes an entity
AuroMedics Pharma LLC begins selling and distributing Injectables in the USA
Commenced operations of SEZ Unit VII and Aurolife, USA facilities and divested Chinese antibiotics products facility
Aurolife Pharma LLC begins manufacturing solid oral dose.
Acquired formulations facility in USA
Investment in building manufacturing, marketing & IPR capabilities
Acquired building from Sandoz to begin Aurolife Manufacturing in Dayton, NJ, USA
Aurobindo Pharma USA, Inc. becomes incorporated in USA
Commencement of export of APIs
Initial Public Offering (1995)
Began production of formulations